|
Red Cross and Novo Nordisk announce ground-breaking partnership to tackle chronic care in humanitarian crises
|
19 April 2018 |
|
Novo Nordisk has proposed to acquire Ablynx for upto €30.50 per share in cash, consisting of €28.00 upfront and €2.50 in Contingent Value Rights
|
08 January 2018 |
|
Interim results of first-ever global survey show people with type 2 diabetes underestimate their cardiovascular risk
|
06 December 2017 |
|
New US study reveals key reasons why millions of people with obesity are not receiving adequate care
|
01 November 2017 |
|
IDF and Novo Nordisk launch first-ever global survey on cardiovascular disease awareness among people with type 2 diabetes
|
29 September 2017 |
|
More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments
|
12 September 2017 |
|
Victoza® reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events
|
28 August 2017 |
|
Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial
|
15 June 2017 |
|
Call for applications: 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award
|
07 June 2017 |
|
Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment
|
03 April 2017 |